PoliPsy tracks 237 psychedelic policy bills across 41 U.S. states and 346 clinical trials covering psilocybin, MDMA, LSD, DMT, ibogaine, and mescaline.
| Bill | State | Substance | Type | Status | Sponsor | Last action |
|---|---|---|---|---|---|---|
| SB1224 - The California Emerging Therapies Research Partnership Act. | California | Psilocybin | Clinical Research | Passed Committee | Brian Jones | Aug 13, 2026 |
| SB43 - Provides relative to psychedelic-assisted therapy. (8/1/26) | Louisiana | Psilocybin | Therapeutic Access | Signed into Law | Patrick McMath | Aug 1, 2026 |
| H4200 - Authorizing a pilot for the use of psychedelics in licensed treatment facilities | Massachusetts | Psilocybin | Clinical Research | In Committee | James O'Day | Jul 23, 2026 |
| H2203 - Establishing a pilot program for access to regulated psilocybin | Massachusetts | Psilocybin | Clinical Research | In Committee | Marjorie Decker | Jul 22, 2026 |
| HB1772 - Relative to prescribing ibogaine for investigational use only. | New Hampshire | Ibogaine | Clinical Research | Signed into Law | Michael Moffett | Jul 20, 2026 |
| HB9559 - IBOGAINE Act Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act | Federal | Multiple | Therapeutic Access | In Committee | Morgan Luttrell | Jul 17, 2026 |
| H4986 - Relative to therapeutic psilocybin treatment centers | Massachusetts | Psilocybin | Therapeutic Access | Passed Committee | Joint Committee on Public Health | Jul 9, 2026 |
| SB1188 - Approved medications; scheduling; prescription authority | Arizona | Psilocybin | Therapeutic Access | Signed into Law | Thomas Shope | Jun 22, 2026 |
| SB1752 - Mescaline; possession; sale; commercial use | Arizona | Mescaline | Therapeutic Access | Passed One Chamber | Theresa Hatathlie | Jun 13, 2026 |
| SB1538 - Controlled substances; approval; workers' compensation | Arizona | Psilocybin | Therapeutic Access | Passed One Chamber | Kevin Payne | Jun 11, 2026 |
| HB6020 - Health: research; participation in ibogaine clinical trials; provide for. Amends sec. 7212 of 1978 PA 368 (MCL 333.7212) & adds secs. 2222, 2222a & 2222b. | Michigan | Ibogaine | Clinical Research | In Committee | Jaime Greene | Jun 9, 2026 |
| HB1325 - Natural Medicine | Colorado | Psilocybin | Therapeutic Access | Signed into Law | Jarvis Caldwell | Jun 4, 2026 |
| SB00191 - An Act Concerning The Psychedelic-assisted Therapy Pilot Program. | Connecticut | Psilocybin | Clinical Research | Signed into Law | Public Health Committee | Jun 4, 2026 |
| SB2149 - AN ACT to amend Tennessee Code Annotated, Title 9; Title 33; Title 53; Title 63 and Title 68, relative to clinical trials. | Tennessee | Psilocybin | Clinical Research | Signed into Law | Page Walley | May 27, 2026 |
| HB2075 - AN ACT to amend Tennessee Code Annotated, Title 9; Title 33; Title 53; Title 63 and Title 68, relative to clinical trials. | Tennessee | Psilocybin | Clinical Research | Signed into Law | Bryan Terry | May 27, 2026 |
View all psychedelic legislation
| Trial | Drug | Phase | Status | Sponsor | Conditions | Start date |
|---|---|---|---|---|---|---|
| Safety Profile of Psilocybin for Cocaine Use Disorder | Psilocybin | Early Phase 1 | Suspended | University of California, Los Angeles | Cocaine Use Disorder | Feb 1, 2029 |
| Psilocybin for Methamphetamine Use Disorder | Psilocybin | Phase 2 | Not Yet Recruiting | Peter Hendricks | Methamphetamine Use Disorder | Feb 1, 2027 |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | Psilocybin | Phase 1 | Not Yet Recruiting | University of Minnesota | Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms, Emotion Dysregulation, Suicidal Ideation | Dec 1, 2026 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | Psilocybin | Phase 1 | Not Yet Recruiting | Charles Raison | Aging, Longevity, Biomarkers of Aging | Dec 1, 2026 |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | Psilocybin | Phase 1 | Recruiting | Brown University | Phase I | Nov 1, 2026 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Psilocybin | Phase 2 | Not Yet Recruiting | Nicky Mehtani, MD, MPH | Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Nov 1, 2026 |
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | MDMA | Phase 2 | Not Yet Recruiting | Jenna M. Traynor | Posttraumatic Stress Disorder (PTSD) | Oct 31, 2026 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Psilocybin | Phase 2 | Recruiting | National Institute on Aging (NIA) | Alzheimer's Disease | Oct 14, 2026 |
| Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors | Psilocybin | N/A | Recruiting | St. Jude Children's Research Hospital | Survivors of Childhood Cancer, Substance Use | Oct 1, 2026 |
| Shortened LSD Intervention for Major Depressive Disorder | LSD | Phase 1 | Not Yet Recruiting | Johns Hopkins University | Major Depression Moderate, Major Depression Severe, Major Depression | Oct 1, 2026 |
View all psychedelic clinical trials